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AQLQ: Asthma Quality of Life Questionnaire
CRS: Chronic rhinosinusitis
CRSwNP: Chronic rhinosinusitis with nasal polyps
FAS: Full analysis set
FESS: Functional endoscopic sinus surgery
HRQoL: Health-related quality of life
INCS: Intranasal corticosteroid
LSM: Least-squares mean
MCID: Minimal clinically important difference
NCS: Nasal Congestion Score
NPS: Nasal Polyp Score
NSAID: Nonsteroidal anti-inflammatory drug
OR: Odds ratio
QoL: Quality of life
SCS: Systemic corticosteroid
SNOT-22: Sino-Nasal Outcome Test-22
TNSS: Total Nasal Symptom Score
UPSIT: University of Pennsylvania Smell Identification Test
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596 GEVAERT ET ALBackground: Chronic rhinosinusitis with nasal polyps
(CRSwNP) is characterized by IgE hyperproduction and
eosinophilic inflammation. The anti-IgE antibody, omalizumab,
has demonstrated efficacy in patients with CRSwNP and
comorbid asthma previously.
Objective: Our aim was to determine omalizumab safety and
efficacy in CRSwNP in phase 3 trials (POLYP 1 and POLYP 2).
Methods: Adults with CRSwNP with inadequate response to
intranasal corticosteroids were randomized (1:1) to omalizumab
or placebo and intranasal mometasone for 24 weeks. Coprimary
end points included change from baseline to week 24 in Nasal
Polyp Score (NPS) and Nasal Congestion Score. Secondary end
points included change from baseline to week 24 in Sino-Nasal
Outcome Test-22 (SNOT-22) score, University of Pennsylvania
Smell Identification Test, sense of smell, postnasal drip, runny
nose, and adverse events.
Results: Patients in POLYP 1 (n 5 138) and POLYP 2 (n 5 127)
exhibited severe CRSwNP and substantial quality of life
impairment evidenced by a mean NPS higher than 6 and SNOT-
22 score of approximately 60. Both studies met both the
coprimary end points. SNOT-22 score, University of
Pennsylvania Smell Identification Test score, sense of smell,
postnasal drip, and runny nose were also significantly improved
for omalizumab versus placebo. In POLYP 1 and POLYP 2, the
mean changes from baseline at week 24 for omalizumab versus
placebo were as follows: NPS, –1.08 versus 0.06 (P < .0001) and
–0.90 versus –0.31 (P 5 .0140); Nasal Congestion Score, –0.89
versus –0.35 (P 5 .0004) and –0.70 versus –0.20 (P 5 .0017); and
SNOT-22 score, –24.7 versus –8.6 (P < .0001) and –21.6 versus
–6.6 (P < .0001). Adverse events were similar between groups.
Conclusion: Omalizumab significantly improved endoscopic,
clinical, and patient-reported outcomes in severe CRSwNP with
inadequate response to intranasal corticosteroids, and it was
well tolerated. (J Allergy Clin Immunol 2020;146:595-605.)
Key words: Nasal polyps, rhinosinusitis, omalizumab, quality of
life, nasal obstruction, IgE, allergy, asthma
Chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP),
also referred to as nasal polyposis, is a severe form of CRS. CRS is
common and is estimated to affect up to 15% of the population
based on a symptomatic definition1 and 3% to 6.7% of the popu-
lation based on symptoms combinedwith endoscopic evaluation.2
A recent large single-center study from the United States reported
that approximately 18% of patients with CRS have CRSwNP.3
CRSwNP is associated with adult-onset asthma, significant
morbidity, decreased health-related quality of life (HRQoL),4-8
and substantial economic burden (amounting to more than $22
billion for CRS in the United States in 2014).9,10 Quality of life
(QoL) impairment is comparable with that experienced by pa-
tients with chronic lower back pain.11 Many patients with
CRSwNP have uncontrolled symptoms despite use of intranasal
corticosteroids (INCS) or systemic corticosteroids (SCS), use of
doxycycline to reduce inflammation or infection, or functional
endoscopic sinus surgery (FESS).4,12 Furthermore, disease con-
trol is poor, with 20% to 80% of patients experiencing recurrence
depending on follow-up duration.13-15
IgE is thought to play a central role in CRSwNP pathogenesis
by activating type 2 inflammatory cells such as mast cells,
basophils, and eosinophils (Fig 1).16 Local IgE class switching byB cells and IgE production is well documented in tissue from pa-
tients with CRSwNP.17-19Within the sinonasal mucosa, Staphylo-
coccal enterotoxin–specific IgE and polyclonal IgE for inhalant
allergens, as well as colonization by microbial agents including
Staphylococcus aureus, are associated with CRSwNP irrespective
of atopic status.20 Locally produced IgE appears to be functional
and involved in regulating chronic inflammation.21
In real-world and randomized clinical studies, patients treated
with the anti-IgE mAb, omalizumab, demonstrated reductions in
CRS-related symptoms, endoscopic Nasal Polyp Score (NPS),
and need for INCS use.22-24 Improvements were observed by
week 4 and were similar to those observed in patients receiving
FESS.23 In a randomized controlled trial of 24 patients with
CRSwNP with comorbid asthma, omalizumab significantly
improved endoscopic NPS, Lund-Mackay score (a validatedmea-
sure of paranasal sinus occupation severity), and patient-reported
outcomes irrespective of atopic status.24
On the basis of these proof-of-concept studies,22-24 2 phase 3
studies (POLYP 1 and POLYP 2) were conducted to evaluate
the efficacy and safety of omalizumab versus placebo in adult pa-
tients with CRSwNP with inadequate response to INCS therapy.METHODS
Study design and patient population
POLYP 1 (NCT03280550) and POLYP 2 (NCT03280537) were replicate
(identical), phase 3, randomized, multicenter, double-blind, placebo-
controlled studies evaluating the efficacy and safety of omalizumab in patients
with inadequately controlled CRSwNP despite daily INCS therapy. They were
conducted across 82 centers in North America and Europe between November
15, 2017, andMarch 11, 2019 (POLYP 1) and November 21, 2017, andMarch
7, 2019 (POLYP 2).
Patients aged 18-75 years with persistent bilateral nasal polyps, nasal
congestion, impaired HRQoL, and weight and serum IgE level permitting
omalizumab dosing per Table E1 (in this article’s Online Repository at www.
jacionline.org) (ie, weight of 30-50 kg and serum IgE level of 30-1500 IU/mL)
were eligible. Patients were required to have received at least 4 weeks of INCS
therapy before screening visit 1 and have a total NPS of 5 or higher (NPS>_2 for
each nostril) at screening visit 1 (day –35). Patients were further required to
have an NPS of 5 or higher at screening visit 2 (day –7), after 4 weeks of
FIG 1. Role of IgE and proposed mechanism of action in chronic rhinosinusitis with nasal polyps. DC, Den-
dritic cell; FcεRI, high-affinity IgE receptor; ILC2, type 2 innate lymphoid cell; PGD2, prostaglandin D2; TSLP,
thymic stroma–derived lymphopoietin.
J ALLERGY CLIN IMMUNOL
VOLUME 146, NUMBER 3
GEVAERT ET AL 597intranasal mometasone during run-in (200 mg twice daily or 200 mg daily if
unable to tolerate 200 mg twice daily). A Nasal Congestion Score (NCS) of
2 or higher (with additional symptoms of postnasal drip, runny nose, and/or
loss of sense of smell) at day –35 (1-week recall) and a weekly mean NCS
higher than 1 at randomization (assessed every morning via an eDiary) were
required (see the section Methods E1 in this article’s Online Repository at
www.jacionline.org). Patients were required to have a Sino-Nasal Outcome
Test-22 (SNOT-22) score of 20 or higher at day –35 and randomization.
Patients were excluded if they had other sinonasal or pulmonary disorders
(except asthma), including the following: current upper respiratory tract
infection, cystic fibrosis, or other dyskinetic ciliary syndrome; past or current
malignancy; a cardiac condition; hepatitis; liver cirrhosis; recent or current
infection requiring hospitalization (<_4 weeks), antibiotic (<_2 weeks) or
antifungal treatment, or parasitic infection (<_6 months); recent use of an
SCS (<_2 months), immunosuppressant, biologic, or leukotriene antagonist or
modifier; recent nasal surgery (<_6 months); known allergy to omalizumab; or
those who were immunocompromised.
Patients were randomized (1:1) to omalizumab or placebo and background
intranasal mometasone for 24 weeks (Fig 2). The protocol specified study
dosing of 75 to 600 mg by subcutaneous injection every 2 or 4 weeks, depend-
ing on the pretreatment serum total IgE level and body weight (see Table E1).
Permuted block randomization (block size 4) was performed by using an inter-
active web-based response system within strata defined by comorbid asthma/
aspirin sensitivity and geographic region. The investigator, investigational site
staff, central image readers, sponsor and sponsor’s representatives, and
patients were blinded to treatment allocation.
Saline nasal lavages were permitted during the study. However, because
antibiotics are often used to treat CRSwNP, systemic antibiotic therapy for
more than 14 days was not permitted during the study. A complete list of
prohibited medications and procedures are in the section Methods E1.
The protocol was approved by the studies’ respective institutional review
boards or ethics committees. All patients provided written informed consent.
The study was conducted in accordance with the International Conference on
Harmonisation GoodClinical Practice,25 the Declaration of Helsinki,26 and all
applicable laws and regulations.Assessments
Demographic data and medical history were collected during screening
visit 1. Blood samples were collected at screening and at weeks 16, 24, and 28
for routine analyses. Serum IgE levels were determined at baseline. NPS
(point range, 0-8 [see Table E2 in this article’s Online Repository at www.
jacionline.org]) was determined for each nasal passage at screening and at
weeks 4, 8, 16, and 24. Endoscopic videos were scored at a central reading
center by 2 blinded independent trained otolaryngologists. Discrepancies
were adjudicated by a third blinded otolaryngologist. Nasal symptoms were
recorded dailywith the use of an eDiary (with nasal congestion, sense of smell,
postnasal drip, and runny nose each assigned a score ranging from 0 [not at all]
to 3 [severe]); each component was analyzed separately and in a combined
summed Total Nasal Symptom Score (TNSS) (point range, 0-12 [see Table
E3 in this article’s Online Repository at www.jacionline.org]). The nasal
congestion question forms the NCS. The University of Pennsylvania Smell
Identification Test (UPSIT) was performed at day 1 and at weeks 8, 16, and
24 (point range, 0-40, with higher scores indicating better smell). SNOT-22
scorewas measured at screening; on day 1; and at weeks 4, 8, 16, and 24 (point
range, 0-110, with lower scores indicating better disease control and QoL). In
patients with comorbid asthma, the Asthma Quality of Life Questionnaire
(AQLQ) was administered at day 1 and at weeks 16 and 24 (point range,
1-7, with higher scores indicating better QoL). Adverse events (AEs) and
concomitant medications were monitored throughout treatment and safety
follow-up.
An open-label extension study will assess patients who received 24 weeks
of open-label omalizumab followed by a 24-week off-drug observation period
(see the section Methods E1).
Outcomes
The coprimary end points were change from baseline to week 24 in
endoscopic NPS24 and mean daily NCS. Secondary end points included
change from baseline at week 24 in SNOT-22 score, UPSIT (a widely used
measure recommended by British Medical Journal Best Practice Guidelines
to assess olfactory function in nasal polyps27) score, mean daily sense of smell,
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Intranasal corticosteroids, background treatment*
FIG 2. Study design for POLYP 1 and POLYP 2. *All patients received intranasal corticosteroids (mometa-
sone nasal spray) as background therapy. Q2W, Every 2 weeks; Q4W, every 4 weeks; SFU, safety follow-up.
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598 GEVAERT ET ALpostnasal drip, runny nose, and TNSS; change from baseline at week 16 in
NPS and NCS; and percentage of patients requiring rescue therapy (an SCS
for >_3 consecutive days and/or nasal polypectomy) by week 24. Reduction
in need for surgery through week 24 was predefined as achievement of an
NPS of 4 or lower (<_2 for each nostril) and an improvement of at least the min-
imal clinically important difference (MCID28;>_8.9 points) in SNOT-22 score.
The percentage of patients with comorbid asthma demonstrating an MCID in
improvement (>_0.5 points) in AQLQ score throughweek 24was also assessed.
Exploratory end points included percentage of patients in the pooled popula-
tion achieving at least a 2-point or at least a 1-point improvement in NPS and at
least a 1-point improvement in NCS.
AEswere assessed for severity and potential causal relationship to the study
drug. Patients were monitored to week 28 as a safety follow-up. AEs were
reported for the pooled POLYP 1 and POLYP 2 population.Statistical analyses
A sample size of 120 patients was calculated to provide at least 85% power
to detect a 0.56-point between2treatment group difference in change from
baseline to week 24 in mean daily NCS and a 1.50-point between2treatment
group difference in mean change from baseline to week 24 in NPS. The
corresponding assumed SDs were 0.83 and 2.2.24,29,30
The full analysis set (FAS) included all randomized patients who received
at least 1 dose of study drug according to assigned treatment group. The safety
analysis set included all patients who received at least 1 dose of study drug
according to treatment received. Randomized patients were treated with the
study drug; both analysis sets were identical in POLYP 1 and differed by 1
patient in POLYP 2. Safety and tolerability results were described for the FAS
by using summary statistics. Patient demographic and clinical characteristics
and efficacy end points were evaluated by using the FAS. Sequential testing
type 1 error control procedures are described in the section Methods E1. All
95% CIs are unadjusted for multiplicity. The within-group means and
between-group differences in absolute change from baseline to week 24
were the estimated least squares means (LSMs) obtained by using a mixed-
effect model with repeated measures with unstructured covariance matrix,
adjusted for comorbid asthma/aspirin sensitivity, geographic region, time
point per schedule of assessments, baseline outcome score, treatment by
time point interaction, and baseline outcome score by time point interaction
for NCS, UPSIT score, SNOT-22 score, and TNSS. P values were derived
from a t test of difference in LSMs.
The between-group difference in the proportion of patients at week 24 with
reduced need for surgery was estimated by using a logistic regression modelanalysis adjusted for the aforementioned baseline covariates, baseline NPS,
and SNOT-22 score. The between-group difference in the proportion of
patients requiring rescue treatment by week 24 was estimated by using a
logistic regression model analysis for oral corticosteroid use for 3 or more
consecutive days and/or sinus surgery adjusted for baseline covariates (see
earlier). The between-group differences in the proportion of patients with
comorbid asthma by week 24 was estimated by using a logistic regression
model analysis adjusted for baseline covariates (see earlier) and baseline
AQLQ score. P values for between-group differences in proportions were
derived from a Wald chi-square test of the treatment effect coefficient in the
logistic regression model.RESULTS
Study disposition, baseline demographics, and
clinical characteristics of patients
In POLYP 1, 138 of 355 screened patients were randomized. In
POLYP 2, 127 of 329 screened patients were randomized (Fig 3).
In POLYP 1, 95.8% of patients treated with omalizumab (69 of
72) and 97.0% of patients in the placebo group (64 of 66)
completed the study. In POLYP 2, 93.5% of patients treated
with omalizumab (58 of 62) and 96.9% of those in the placebo
group (63 of 65) completed the study. Five patients (3 who
received omalizumab and 2 who received placebo) in POLYP 1
and 6 patients (4 who received omalizumab and 2 who received
placebo) in POLYP 2 discontinued the study. Reasons for discon-
tinuation included patient decision (2 patients in POLYP 1 and 4
in POLYP 2) and investigator decision (1 patient in POLYP 1) for
the omalizumab groups and patient decision for the placebo
groups (2 patients in POLYP 1 and 2 in POLYP 2).
Demographics and clinical characteristics were similar be-
tween treatment groups and across the studies (Table I). Patients
had severe nasal polyps and/or symptoms at baseline (mean NPS
>6), significant loss of smell (mean UPSIT score, 12.8-13.9
[81.5% of patients had anosmia]), and substantial CRSwNP-
related HRQoL impairment (mean SNOT-22 score, 59.2-60.5).
Across the studies, 48.5% to 61.3% of patients had
comorbid asthma; most had mild (35.1%) or moderate
(58.3%) physician-assessed asthma severity. Nonsteroidal
POLYP 1
Screened, n = 355
Excluded, n =  217
Randomized, n = 138
Placebo, n = 66 Omalizumab, n = 72
Discontinued           2
    Patient decision   2
Discontinued                   3
    Patient decision           2
    Investigator decision   1
Completed, n = 64 Completed, n = 69
POLYP 2
Screened, n = 329
Excluded, n =  202
Randomized, n = 127
Placebo, n = 65 Omalizumab, n = 62
Discontinued            2
    Patient decision    2
Discontinued             4
    Patient decision     4
Completed, n = 63 Completed, n = 58
FIG 3. Patient disposition (Consolidated Standards of Reporting Trials flow diagram).
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(or aspirin-exacerbated respiratory disease) was present in 27.2%
of patients.
Across the studies, 12.1% to 29.0% of patients used an SCS in
the prior year and 59.6%of patients had undergone prior sinonasal
surgery. Most patients (92.3%-96.8%) received the maximum
allowed mometasone dosag during run-in and treatment. Most
patients (90.4% in the pooled omalizumab arms and 86.9% in the
pooled placebo arms) were assigned to receive omalizumab or
placebo every 4 weeks, with similar dose and dosing frequency
across the studies and between treatment groups (Table I).Changes in NPS and NCS
Both studies met their coprimary end points, with omalizumab-
treated patients achieving statistically significant improvements
in mean NPS and daily NCS at week 24 versus placebo. The mean
changes in NPS for omalizumab versus placebo from baseline at
week 24 were –1.08 versus 10.06 (treatment arm difference,
–1.14 [95% CI 5 –1.59 to –0.69; P < .0001]) in POLYP 1 and
–0.90 versus –0.31 (treatment arm difference, –0.59 [95% CI 5
–1.05 to –0.12; P 5 .0140]) in POLYP 2. The mean changes for
omalizumab versus placebo in NCS from baseline to week 24
were –0.89 versus –0.35 (treatment arm difference, –0.55 [95%
CI 5 –0.84 to –0.25; P 5 .0004]) in POLYP 1 and –0.70 versus
–0.20 (treatment arm difference, –0.50 [95% CI 5 –0.80 to
–0.19; P 5 .0017]) in POLYP 2, respectively (Table II). The
between-treatment group differences at week 16 were similar to
those at week 24 for NPS and NCS (Table II). Greater improve-
ments in NPS and NCS for omalizumab versus placebo were
observed as early as week 4 (first assessment) in both studies
(Fig 4, A and B). The mean changes from baseline at week 4 in
NPS for omalizumab versus placebo were –0.92 (95% CI 5
–1.37 to –0.48) in POLYP 1 and –0.52 (95% CI 5 –0.94 to
–0.11) in POLYP 2. The mean changes from baseline at week 4
in NCS for omalizumab versus placebo were –0.25 (95% CI 5
–0.46 to –0.04) in POLYP 1 and –0.26 (95% CI 5 –0.45 to
–0.07) in POLYP 2.
A greater percentage of omalizumab-treated patients had
improved NPS and NCS at week 24 versus placebo in the pooled
population. One-point or greater and 2-point or greaterimprovements in NPS were observed in 56.3% (72 of 128) and
31.3% (40 of 128) of omalizumab-treated patients and 28.7% (37
of 129) and 11.6% (15 of 129) of placebo-treated patients,
respectively. A 1-point or greater improvement in NCS was
observed in 56 of 126 omalizumab-treated patients (44.4%) and in
27 of 126 placebo-treated patients (21.4%) (Fig 5).
Patients with comorbid asthma and NSAID-exacerbated res-
piratory disease in the pooled population had similar mean
improvements in NPS and NCS at week 24 compared with
patients without NSAID-exacerbated respiratory disease (see Fig
E1 in this article’s Online Repository at www.jacionline.org).Secondary efficacy end points
Statistically significant improvements favoring omalizumab
were observed in both studies for SNOT-22 score, UPSIT score,
TNSS, and individual nasal symptoms (sense of smell, postnasal
drip, runny nose) from baseline at week 24 (Table II and Fig 6, A-
C). In an exploratory analysis of prior time points, effects were
observed as early as the first time point assessed (week 4 for
most end points, week 8 for UPSIT score). The LSM difference
in change from baseline at week 4 in SNOT-22 score with omali-
zumab versus placebo was –10.43 (95% CI5 –15.08 to –5.79) in
POLYP 1 and –8.84 (95%CI5 –13.84 to –3.84) in POLYP 2. The
LSMdifference in change from baseline at week 8 inUPSIT score
for omalizumab versus placebowas 3.78 (95%CI5 1.56-6.00) in
POLYP 1 and 3.44 (95% CI 5 1.03-5.85) in POLYP 2.
The odds of achieving at least a 0.5-point improvement in
AQLQ score (MCID) were approximately 4 times higher for
omalizumab- versus placebo-treated patients with comorbid
asthma (for POLYP 1, odds ratio [OR] 5 3.7 [95% CI 5
1.0-13.7; P 5 .0492]; for POLYP 2, OR 5 4.0 [95% CI 5
1.1-15.3; P 5 .0396]) (Table III).
Rescue SCS therapy was required in 8 of 129 placebo-treated
patients (6.2%) and 3 of 129 omalizumab-treated patients (2.3%)
from the pooled population during the study, favoring omalizu-
mab with a 62.5% relative reduction (a 3.9% absolute difference)
in rescue steroid use (P 5 .16). No sinus surgeries or polypecto-
mies were recorded. A reduced need for surgery by week 24
was observed in 2 of 65 placebo-treated patients (3.1%) and 13
of 69 omalizumab-treated patients (18.8%) from POLYP 1
TABLE I. Baseline characteristics of randomized patients
Characteristic
POLYP 1 POLYP 2
Placebo (n 5 66) Omalizumab (n 5 72) Placebo (n 5 65) Omalizumab (n 5 62)
Age (y), mean (SD)* 52.2 (11.6) 50.0 (14.5) 51.0 (12.0) 49.0 (11.9)
Male, no. (%)* 41 (62.1) 47 (65.3) 44 (67.7) 39 (62.9)
BMI (mg/kg2), mean (SD) 27.7 (5.3) 27.4 (4.8) 28.1 (5.0) 26.9 (4.1)
Geographic region, no. (%)
North America 19 (28.8) 23 (31.9) 14 (21.5) 12 (19.4)
Europe 47 (71.2) 49 (68.1) 51 (78.5) 50 (80.6)
Tobacco use, no. (%)
Current smoker 6 (9.1) 6 (8.3) 8 (12.3) 7 (11.3)
Former smoker 13 (19.7) 11 (15.3) 18 (27.7) 15 (24.2)
NPS (range, 0-8), mean (SD) 6.3 (0.9) 6.2 (1.0) 6.1 (0.9) 6.4 (0.9)
NCS (range, 0-3), mean (SD) 2.5 (0.6) 2.4 (0.7) 2.3 (0.6) 2.3 (0.7)
Sense of smell score (range, 0-3), mean (SD) 2.8 (0.4) 2.5 (0.8) 2.8 (0.6) 2.6 (0.8)
Postnasal drip score (range, 0-3), mean (SD) 2.0 (0.9) 1.7 (0.9) 1.8 (0.9) 1.6 (0.9)
Runny nose score (range, 0-3), mean (SD) 2.1 (0.8) 1.9 (0.8) 1.9 (0.8) 1.9 (0.9)
TNSS (range, 0-12), mean (SD) 9.3 (1.9) 8.6 (2.5) 8.7 (2.3) 8.4 (2.6)
UPSIT score (range, 0-40), mean (SD) 13.9 (7.4) 12.8 (7.9) 13.1 (7.3) 12.8 (7.6)
SNOT-22 score (range, 0-110), mean (SD) 60.5 (15.3) 59.8 (19.7) 59.8 (18.2) 59.2 (20.5)
Comorbid asthma, no. (%) 32 (48.5) 42 (58.3) 39 (60.0) 38 (61.3)
Physician-assessed asthma severity, no. (%)
Mild 15 (46.9) 13 (31.0) 13 (33.3) 12 (31.6)
Moderate 16 (50.0) 27 (64.3) 25 (64.1) 20 (52.6)
Severe 1 (3.1) 2 (4.8) 1 (2.6) 6 (15.8)
AQLQ score, mean (SD)* 4.8 (1.3) 4.5 (1.5) 5.2 (1.3) 4.9 (1.2)
NSAID-exacerbated respiratory disease
(AERD), no. (%)
11 (16.7) 16 (22.2) 21 (32.3) 24 (38.7)
Serum total IgE (IU/mL), mean (SD) 162.0 (141.2) 159.9 (139.0) 196.1 (200.6) 184.1 (201.9)
Blood eosinophils (cells/mL), mean (SD) 358.6 (305.2) 334.4 (264.7) 357.4 (196.2) 310.8 (176.6)
SCS use in past year, no. (%) 8 (12.1) 18 (25.0) 15 (23.1) 18 (29.0)
Courses of SCS, no. (%)
1 5 (62.5) 9 (50.0) 6 (40.0) 11 (61.6)
>_2 2 (25.0) 7 (38.9) 9 (60.0) 5 (27.8)
Unknown 1 (12.5) 2 (11.1) 0 (0.0) 2 (11.1)
Previous NP surgery, no. (%) 40 (60.6) 39 (54.2) 40 (61.5) 39 (62.9)
No. of previous NP surgeries, no. (%)
1 24 (36.4) 23 (31.9) 15 (23.1) 22 (35.5)
>_2 16 (24.2) 16 (22.2) 25 (38.5) 17 (27.4)
Time since last NP surgery, no. (%)
>12 mo to 5 y 13 (32.5) 9 (23.1) 12 (30.0) 9 (24.3)
>5 y 27 (67.5) 30 (76.9) 28 (70.0) 28 (75.7)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 2 (5.1)
Mometasone dose prescribed, no. (%)
200 mg daily 4 (6.1) 4 (5.6) 5 (7.7) 2 (3.2)
200 mg twice daily 62 (93.9) 68 (94.4) 60 (92.3) 60 (96.8)
Planned dosing schedule for study drug, no. (%)
Every 4 weeks 61 (92.4) 67 (93.1) 52 (81.3) 55 (87.3)
Every 2 weeks 5 (7.6) 5 (6.9) 12 (18.8) 8 (12.7)
AERD, Aspirin-exacerbated respiratory disease; BMI, body mass index; NP, nasal polyp.
*In POLYP 2: placebo, n 5 64.
Higher scores indicate worse health status.
Higher scores indicate better sense of smell; UPSIT score of 0 to 18 indicates a total loss of smell/anosmia.
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placebo-treated patients (3.2%) and 10 of 59 omalizumab-
treated patients (16.9%) from POLYP 2 (OR 5 6.2 [95% CI 5
1.2-60.2; P 5 .0139]) (Table III).Safety and tolerability
The proportions of patients who experienced at least 1
treatment-emergent AE were 58.5% in placebo-treated patients
and 50.4% in omalizumab-treated patients. The number of AEswas greater in placebo-treated patients than in omalizumab-
treated patients. Most events across both studies were of mild to
moderate intensity. Two serious AEs were reported in placebo-
treated patients (1.5% [1 case of myocardial infarction and 1 case
of pneumonia]) and 3 were reported in omalizumab-treated
patients (2.2% [1 case of snake bite, 1 hand fracture, and 1 case
of asthma exacerbation/worsening]). The proportion of patients
experiencing at least 1 AE suspected by the investigator to be
omalizumab related was 3.8% in placebo-treated patients versus
6.7% in omalizumab-treated patients. These AEs were mild to
TABLE II. Primary and secondary efficacy end points
End point












arm differencesy P value
Primary end point at week 24
NPS (range, 0-8) 0.06 (0.16) –1.08 (0.16) –1.14 (–1.59 to –0.69) <.0001 –0.31 (0.16) –0.90 (0.17) –0.59 (–1.05 to –0.12) .0140
NCS (range, 0-3) –0.35 (0.11) –0.89 (0.10) –0.55 (–0.84 to –0.25) .0004 –0.20 (0.11) –0.70 (0.11) –0.50 (–0.80 to –0.19) .0017
Secondary end point at week 16
NPS (range, 0-8) 0.03 (0.15) –0.98 (0.14) –1.01 (–1.43 to –0.60) <.0001 –0.29 (0.16) –1.20 (0.17) –0.91 (–1.39 to –0.44) .0002
NCS (range, 0-3) –0.32 (0.10) –0.89 (0.09) –0.57 (–0.83 to –0.31) <.0001 –0.21 (0.10) –0.80 (0.10) –0.59 (–0.87 to –0.30) <.0001
Secondary end point at week 24
SNOT-22 score
(range, 0-110)
–8.58 (2.08) –24.70 (2.01) –16.12 (–21.86 to –10.38) <.0001 –6.55 (2.19) –21.59 (2.25) –15.04 (–21.26 to –8.82) <.0001
UPSIT score
(range, 0-40)
0.63 (0.90) 4.44 (0.84) 3.81 (1.38-6.24) .0024 0.44 (0.81) 4.31 (0.83) 3.86 (1.57-6.15) .0011
TNSS (range, 0-12) –1.06 (0.34) –2.97 (0.33) –1.91 (–2.85 to –0.96) .0001 –0.44 (0.32) –2.53 (0.33) –2.09 (–3.00 to –1.18) <.0001
Loss of smell score
(range, 0-3)
–0.23 (0.10) –0.56 (0.09) –0.33 (–0.60 to –0.06) .0161 –0.13 (0.10) –0.58 (0.10) –0.45 (–0.73 to –0.16) .0024
Postnasal drip score
(range, 0-3)
–0.16 (0.10) –0.72 (0.10) –0.56 (–0.84 to –0.28) .0001 –0.00 (0.10) –0.55 (0.10) –0.54 (–0.81 to –0.27) .0001
Runny nose score
(range, 0-3)
–0.34 (0.10) –0.77 (0.10) –0.43 (–0.70 to –0.16) .0023 –0.08 (0.10) –0.70 (0.10) –0.63 (–0.90 to –0.35) <.0001
Pooled analysis of data from POLYP 1 and POLYP 2.
*Data expressed as adjusted means (SEs), with P values unadjusted for multiplicity.
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FIG 4. Mean change from baseline in NPS (A) and NCS (B) in POLYP 1 and POLYP 2.
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GEVAERT ET AL 601moderate in intensity, and most occurred within 24 hours of
administration of the study drug. An episode of anaphylaxis, later
adjudicated as not meeting the Sampson criteria by an indepen-
dent anaphylaxis adjudication committee, led to discontinuation
in the placebo-treated patients. No AEs were reported as
omalizumab-associated risks (Table IV).DISCUSSION
CRSwNP is a chronic, debilitating condition associated with
high symptom burden and substantial impact on QoL, as well as
with allergic comorbidities, including asthma and NSAID-
exacerbated respiratory disease (aspirin-exacerbated respiratorydisease).12,31,32 Many patients fail to achieve sufficient benefit
from INCS therapy and require repeated courses of an SCS and/
or sinus surgeries.12,13Although sinus surgeriesmay be successful
initially, relapse occurs in approximately 20% of patients after 12
months,14 in 40% after 18 months,13 and in 80% after 12 years15
despite ongoing INCS therapy.15 Novel treatments for CRSwNP
are therefore needed. In these replicate, randomized, pivotal,
phase 3 studies of omalizumab in patients with CRSwNP, both co-
primary end points were met, with statistically significant im-
provements frombaseline toweek 24 inmean dailyNCSandNPS.
Improvements in NPS and NCS were accompanied by
significant improvements in patient-reported symptoms and
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FIG 5. Proportion of patients reporting at least a 1-point improvement in NPS and NCS and at least a 2-point
improvement in NPS in POLYP 1 and POLYP 2 (pooled data).
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602 GEVAERT ET ALpostnasal drip, runny nose) and smell test (UPSIT score). These
results may be more intuitively appreciated through the responder
analyses, which demonstrated a greater proportion of omalizu-
mab- versus placebo-treated patients achieving at least a 1-point
(56.3% vs 28.7%) and at least a 2-point (31.3% vs 11.6%)
improvement in NPS and at least a 1-point improvement in NCS
(44.4% vs 21.4%). Asthma-related QoL was also significantly
improved, as was demonstrated by the percentage of patients with
comorbid asthma achieving at least a 0.5-point improvement in
AQLQ score. Improvements above placebo were evident as early
as week 4 for most metrics (week 8 for UPSIT) and were
maintained over the 24-week treatment period, suggesting a rapid
and sustained effect of omalizumab. These data support the
findings of previous studies showing significant improvements in
CRSwNP with omalizumab when similar outcome measures
were used.23
In addition to significant improvements in nasal polyp and
nasal symptom scores, omalizumab led to significant and sub-
stantial improvements in nasal polyp2related QoL in both
studies. In the pooled analysis, omalizumab treatment resulted
in a 23.1-point improvement in SNOT-22 score versus a 7.7-point
improvement in the placebo-treated arm. Placebo-corrected
improvements exceeded the commonly accepted MCID of 8.9
points.28,33 Interestingly, the improvements observed here with
omalizumab were similar to those reported for FESS in a recent
systematic review and meta-analysis of 15 studies (mean change,
23.0 [95% CI 5 20.2-25.8]), which included 3048 patients.34
These findings thus support those by Bidder et al,23 who demon-
strated similar improvements in SNOT-22 score in omalizumab-
and surgically treated patients with CRSwNP.
Patients with asthma are more likely to develop CRSwNP than
are those without asthma, and they are more likely to have severe
disease, receive more oral corticosteroid courses, and experience
relapse requiring multiple endoscopic surgeries.3,35 In the pooled
population, most patients with comorbid asthma had physician-
assessed mild to moderate disease (93.4%). Nonetheless,improvements in AQLQ score were similar to a previous study
in a population with more severe asthma.24 In these studies,
omalizumab-treated patients were 4 times more likely than
placebo-treated patients to achieve an MCID (by >_0.5 points) in
improvement in AQLQ score. Omalizumab may therefore offer
a viable treatment to simultaneously control asthma and
CRSwNP symptoms.
Omalizumab numerically reduced rescue medication use by
approximately two-thirds versus placebo, but the number of
events related to rescue medication was low, making it difficult to
draw conclusions. These steroid-sparing results are similar to
those previously reported in omalizumab studies in patients with
asthma.36,37
Omalizumab was well tolerated, with no new or unexpected
safety concerns identified in the pooled data. The most common
AEs observed (headache, injection site reactions, arthralgia,
dizziness, and upper abdominal pain) have been previously
reported with omalizumab.38-40 The safety profile of omalizumab
is well established in patients with allergic asthma and chronic
idiopathic urticaria,41 with a cumulative exposure of more than
16,000 patient-years in clinical trials and an estimated cumulative
patient exposure of more than 1.3 million patient-years to date in
the postmarketing setting (omalizumab periodic safety update
report, unpublished data, Novartis). Rare events such as anaphy-
laxis (occurring in 0.1%-0.2% of patients with asthma according
to clinical and postmarketing data)42,43 were not observed in these
trials.
These results are strengthened by the study design with
sufficient power to meet the coprimary end points. The baseline
patient characteristics were well balanced between studies and
within treatment arms.
However, the limitations of the present analysis include the
number of patients requiring rescue medication and sinonasal
surgery, which was too low in the pooled population to draw
meaningful conclusions about the benefit of omalizumab in
these areas. Additionally, most patients in the studies had mild
Week
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FIG 6. Change from baseline in SNOT-22 score (A), UPSIT score (B), and TNSS (C) in POLYP 1 and POLYP 2.
TABLE III. Secondary efficacy end points
End point
POLYP 1 POLYP 2
OR (95% CI) P value OR (95% CI) P value
AQLQ score, OR of MCID (>_0.5-point improvement) 3.71 (1.00-13.71) .0492 4.04 (1.07-15.25) .0396
Reduction in need for surgery, NPS <_4 (unilateral score <_2
on each side) and SNOT-22 score improvement >_8.9
6.3 (1.3-29.6) .0209 6.2 (1.2-60.2) .0139
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GEVAERT ET AL 603to moderate asthma, in contrast to patients in the proof-of-
concept study,17 all of whom had severe asthma meeting the
criteria for omalizumab treatment. Although the relative effi-
cacy in more severe asthma cannot be established, asthma co-
morbidity did not appear to be a significant predictor of
response.
In conclusion, the global, replicate, phase 3 studies, POLYP 1
and POLYP 2, met both coprimary end points, demonstrating
statistically significant improvements in NPS and mean daily
NCS as well as patient-reported assessments of severity ofsymptoms in response to omalizumab versus placebo, on a
background of intranasal mometasone, at week 24. Multiple
secondary outcomes were also met. The improvements in SNOT-
22 score illustrate the impact on patient QoL and place the results
into an important context relative to other therapies such as SCS
and surgery. Omalizumab was well tolerated, and AEs were
consistent with those previously reported. Omalizumab repre-
sents a promising new treatment option for patients with
refractory CRSwNP, for whom there is a substantial unmet need
for effective therapies.
TABLE IV. AEs (safety population)
Event
Pooled data
Placebo (n 5 130) Omalizumab (n 5 135)
Total no. of AEs 210 178
Total no. of SAEs* 2 3
Patients with
>_1 AE, no. (%) 76 (58.5) 68 (50.4)
>_1 SAE, no. (%) 2 (1.5) 3 (2.2)
Treatment-related AE, no. (%) 5 (3.8) 9 (6.7)
>_1 AE leading to discontinuation of study drug, no. (%) 1 (0.8) 0 (0.0)
AEs occurring in >_3% of patients
Headache 7 (5.4) 11 (8.1)
Nasopharyngitis 11 (8.5) 8 (5.9)
Injection site terms 2 (1.5) 7 (5.2)
Asthma exacerbation/worsening 15 (11.5) 5 (3.7)
Upper abdominal pain 1 (0.8) 4 (3.0)
Arthralgia 2 (1.5) 4 (3.0)
Back pain 5 (3.8) 4 (3.0)
Dizziness 1 (0.8) 4 (3.0)
Epistaxis 4 (3.1) 4 (3.0)
Rhinitis 4 (3.1) 4 (3.0)
Sinusitis 3 (2.3) 4 (3.0)
Nasal polyps 4 (3.1) 3 (2.2)
Nasal congestion 4 (3.1) 0 (0.0)
AEs identified as risks associated with omalizumab
Serum sickness syndrome/serum sickness–like disease 0 (0.0) 0 (0.0)
Anti-omalizumab antibodies 0 (0.0) 0 (0.0)
Eosinophilic granulomatosis with polyangiitis/Churg-Strauss
syndrome/hypereosinophilic syndrome
0 (0.0) 0 (0.0)
Thrombocytopenia 0 (0.0) 0 (0.0)
Arterial thrombotic events 1 (0.8) 0 (0.0)
Malignant neoplasms 1 (0.8) 0 (0.0)
Parasitic infections 0 (0.0) 0 (0.0)
SAE, Serious adverse event.
*The SAEs in the omalizumab arm were hand fracture, snake bite, and asthma.
Includes injection site reaction, injection-related reaction, and injection site pain.
One patient experienced 1 event of injection site reaction and 1 event of injection site pain.
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Clinical implications: The results from the POLYP 1 and
POLYP 2 trials reinforce the findings of previous trials showing
that omalizumab is a viable alternative treatment for patients
with CRSwNP with inadequate response to intranasal
corticosteroids.REFERENCES
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